ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Uric Acid, Urate"

  • Abstract Number: 2560 • ACR Convergence 2024

    Continuous Reduction in Ultrasound Detected Crystal Depositions over 5 Years Follow-up: Results from the NOR-Gout Study

    Hilde B Hammer1, Lars F Karoliussen1, Lene Terslev2, Espen A. Haavardsholm3 and Tillmann Uhlig1, 1Diakonhjemmet hospital, Oslo, Norway, 2Rigshospitalet-Glostrup & COPECARE, Glostrup, Denmark, 3Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway

    Background/Purpose: Ultrasound (US) is sensitive for detecting monosodium urate (MSU) crystal depositions in gout, described as double contour (DC), tophi and aggregates. Depositions decreased during…
  • Abstract Number: 1085 • ACR Convergence 2024

    Pharmacokinetics and Pharmacodynamics of Tigulixostat in Participants with Mild, Moderate, and Severe Renal Impairment

    Ashish Kumar1, Ali Hariri1, Yunjung Lee2 and Minhyung Lee2, 1LG Chem Life Sciences USA, Boston, MA, 2LG Chem, Seoul, Republic of Korea

    Background/Purpose: Tigulixostat is a potent and highly selective non-purine based xanthine oxidase inhibitor (XOi) being investigated for the management of hyperuricemia in patients with gout.…
  • Abstract Number: 1090 • ACR Convergence 2024

    Hepatic Fibrosis Before and During Intensive Urate-lowering with Pegloticase in the Presence and Absence of Methotrexate Co-therapy

    Naomi Schlesinger1, Katie Obermeyer2, Lissa Padnick-Silver2, Brian LaMoreaux3 and Peter Lipsky4, 1University of Utah, Salt Lake City, UT, 2Amgen, Inc., Thousand Oaks, CA, 3Amgen, Inc., Deerfield, IL, 4AMPEL BioSolutions, Charlottesville, VA

    Background/Purpose: Gout is associated with non-alcoholic fatty liver disease (NAFLD),1 with elevated serum urate (SU) and high flare frequency (≥3 flares/yr) contributing.2 The Fib-4 index, calculated from…
  • Abstract Number: 1091 • ACR Convergence 2024

    Mapping Monosodium Urate Crystal Deposition Within Joints in Tophaceous Gout: A Dual Energy CT Study

    Chamaya De Silva1, César Díaz2, Gregory Gamble3, Anne Horne3, Anthony Doyle3, Lisa Stamp4 and Nicola Dalbeth3, 1Health NZ Waitemata, Auckland, New Zealand, 2Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 3University of Auckland, Auckland, New Zealand, 4University of Otago, Christchurch, Christchurch, New Zealand

    Background/Purpose: In gout, monosodium urate (MSU) crystal deposition occurs preferentially at certain joints, most frequently the first metatarsophalangeal (MTP) joint. Dual energy CT (DECT) allows…
  • Abstract Number: 1878 • ACR Convergence 2024

    The Associations Between Gout and Ischemic Colitis Among Hospitalized Patients: A Retrospective Nationwide Analysis

    Nidaa Rasheed1, Humzah Iqbal2, SRIKAR SAMA3 and candice reyes4, 1UCSF Fresno, Fresno, CA, 2UCSF FRESNO, FRESNO, 3University of California San Francisco Fresno, Fresno, CA, 4VACCHCS, Fresno, CA

    Background/Purpose: Gout is the most common form of inflammatory arthropathy. It occurs due to urate crystal deposition within the joint space, usually in the setting…
  • Abstract Number: 1885 • ACR Convergence 2024

    Effect of Physical Activity on Mortality in Rheumatoid Arthritis: A Dose-Response Analysis

    Bo Chen1 and Qibing Xie2, 1Chenbo, Chendu, Sichuan, China, 2Department of Rheumatology and Immunology, Chengdu, Sichuan, China

    Background/Purpose: Patients with Rheumatoid arthritis (RA) tend to perform less physical activity compared to the recommended guidelines. The long-term effects of physical activity on mortality…
  • Abstract Number: 1898 • ACR Convergence 2024

    Hyperuricemia Is Associated with Higher Levels of Fasting Plasma Glucose and Insulin Resistance in Non-diabetic Subjects

    Janis Timsans1, Jenni Kauppi1, Anne Kerola2, Vappu Rantalaiho3, Hannu Kautiainen4 and Markku Kauppi2, 1Päijät-Häme Central Hospital, Lahti, Finland, 2Päijät-Häme Central Hospital, University of Helsinki, Lahti, Finland, 3Tampere University Hospital, Tampere University and Kanta-Häme Central Hospital, Tampere, Finland, 4Folkhälsan Research Center, Helsinki, Finland

    Background/Purpose: Disorders of glucose metabolism are well-known major contributors to morbidity and mortality. Elevated serum uric acid (SUA), a key precursor of gout attacks, is…
  • Abstract Number: 2005 • ACR Convergence 2024

    Impact of Anti-drug Antibodies on the Efficacy of SEL-212 in Patients with Chronic Gout Refractory to Conventional Therapy

    Puja Khanna1, Vibeke Strand2, Atul Singhal3, Herbert Baraf4, Rehan Azeem5, Wesley DeHaan6, Sheldon Leung5, Hugues Santin-Janin7, Aletta Falk8 and Alan Kivitz9, 1University of Michigan, Ann Arbor, MI, 2Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, 3Southwest Arthritis Research Group, Mesquite, TX, 4Center for Rheumatology and Bone Research, Wheaton, MD, 5Sobi Inc., Waltham, MA, 6Sobi, Inc, Waltham, MA, 7Sobi, BETTENDORF (68560), France, 8Sobi, Stockholm, Sweden, 9Altoona Center for Clinical Research, Duncansville, PA

    Background/Purpose: SEL-212 is a once-monthly, investigational, two-component infusion therapy consisting of pegadricase (SEL-037, a pegylated uricase) and immune-tolerizing nanoparticles containing sirolimus (SEL-110), for the treatment…
  • Abstract Number: 0251 • ACR Convergence 2023

    Sodium-glucose Cotransporter-2 Inhibitor Initiation, Risk of Recurrent Gout Flares, and Mortality in Patients with Gout and Type 2 Diabetes: A Population-based Cohort Study

    Jie Wei1, Hyon K. Choi2, Nicola Dalbeth3, Xiaoxiao Li4, Changjun Li5, Chao Zeng6, Guanghua Lei6 and Yuqing Zhang7, 1Health Management Center, Xiangya Hospital Central South University, Changsha, China, 2Massachusetts General Hospital and Harvard Medical School, Lexington, MA, 3University of Auckland, Auckland, New Zealand, 4Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China, 5National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China, 6Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China, 7Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA

    Background/Purpose: Recurrent flares are the hallmark of clinical manifestation of gout. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) were associated with a lower risk of incident gout; however,…
  • Abstract Number: 1816 • ACR Convergence 2023

    Hyperuricemia – Especially “Metabolic Hyperuricemia” – Is Independently Associated with Higher Risk of Fatty Liver

    Janis Timsans1, Jenni Kauppi1, Hannu Kautiainen2 and Markku Kauppi3, 1Päijät-Häme Central Hospital, Lahti, Finland, 2University of Helsinki, Folkhälsan Research Center, Helsinki, Finland, 3University of Helsinki, Helsinki, Finland

    Background/Purpose: Elevated serum uric acid (SUA) level is rather prevalent in the general population, and it is associated with numerous comorbidities and mortality. Etiology of…
  • Abstract Number: 0753 • ACR Convergence 2023

    Facility Variation in HLA-B*58:01 Allele Testing for Asian and Black Patients Receiving Allopurinol in the Veterans Affairs Healthcare System

    Jeremy Sullivan1, Anna Ware2, Gary Tarasovsky3, Cherish Wilson4, Mary Whooley3, Jasvinder Singh5, Jinoos Yazdany6 and Gabriela Schmajuk4, 1University of California San Francisco, San Francisco, CA, 2Palo Alto VA, Minneapolis, MN, 3San Francisco VA, San Francisco, CA, 4UCSF / SFVA, San Francisco, CA, 5University of Alabama at Birmingham, Birmingham, AL, 6University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA

    Background/Purpose: New guidelines published in 2020 conditionally recommend HLA-B*58:01 allele testing for South Asian and Black patients receiving allopurinol to reduce the risk of severe…
  • Abstract Number: 1909 • ACR Convergence 2023

    Identifying and Addressing Suboptimal Urate Lowering Therapy in Gout Patients with Chronic Kidney Disease

    Lena Eder1 and David Leverenz2, 1Duke University, Chapel Hill, NC, 2Duke University School of Medicine, Durham, NC

    Background/Purpose: Patients with gout and chronic kidney disease (CKD) are often not appropriately managed with goal-directed urate-lowering therapy (ULT). To address deficits in management of…
  • Abstract Number: 0814 • ACR Convergence 2023

    Treat-to-target Urate-lowering Therapy Reduces Gout Flare Burden: Post-hoc Analysis of a Multicenter, Randomized, Double-blind, Non-inferiority Trial

    Joshua Qu1, Lindsay Helget1, Maria Androsenko2, Hongsheng Wu3, Bridget Kramer1, Jefferey Newcomb4, Mary Brophy3, Anne Davis-Karim5, Bryant England1, Ryan Ferguson3, Michael Pillinger6, Tuhina Neogi7, Paul Palevsky8, James O'Dell1 and Ted R Mikuls9, 1University of Nebraska Medical Center, Omaha, NE, 2Department of VA, Newton, MA, 3Boston VA, Boston, MA, 4University of Nebraska, Omaha, NE, 5Albuquerque VA, Albuquerque, NM, 6New York University Grossman School of Medicine, New York, NY, 7Boston University School of Medicine, Boston, MA, 8University of Pittsburgh, Pittsburgh, PA, 9Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: To optimally manage gout, the ACR recommends a treat-to-target (T2T) strategy, which entailsthe titration of urate-lowering therapy (ULT) to achieve and maintain a serum…
  • Abstract Number: 2241 • ACR Convergence 2023

    Guselkumab Efficacy in Active Psoriatic Arthritis Patients with or Without Hyperuricemia: Post-hoc Analysis of Two Phase 3, Randomized, Double-blind, Placebo-Controlled Studies

    Renaud FELTEN1, Laura Widawski2, Lionel Spielman2, Jacques-Eric Gottenberg3, Pierre-Marie Duret2, Emmanouil Rampakakis4, Mohamed Sharaf5, Caren Constantin6, vincenza campana6 and Laurent Messer7, 1Hôpital de Hautepierre, Strasbourg, France, 2Hôpitaux civils de Colmar, Colmar, France, 3Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, 4JSS Medical Research, Saint-Laurent, QC, Canada, 5Immunology, Janssen MEA, Dubai, United Arab Emirates, 6Janssen Cilag Medical Affairs, Issy les Moulineaux, France, 7Laboratoire Interdisciplinaire en études culturelles (LinCS), Strasbourg, France

    Background/Purpose: Patients (pts) with psoriasis (PsO) or PsA are at increased risk for developing gout; and hyperuricemia (HU) prevalence is higher in PsO/PsA pts than…
  • Abstract Number: 1012 • ACR Convergence 2023

    Leveraging Cues and Rewards to Form Habits to Improve Medication Adherence in Gout: An Adaptive Behavioral Pilot Trial

    Candace Feldman1, Katherine Crum2, Kaitlin Hanken3, Constance Fontanet4, Ellen Sears2, Theresa Oduol2, Seanna Vine2, Juliana Mastrorilli2, Gauri Bhatkhande2, Julie Lauffenburger2, Rebecca Oran5, Ted Robertson6, Wendy Wood7 and Niteesh Choudhry3, 1Brigham and Women's Hospital, Boston, MA, 2Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, 3Center for Healthcare Delivery Sciences and Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, 4Darmouth Geisel School of Medicine, Hanover, NH, 5BCBS, Boston, MA, 6Ideas42, San Francisco, CA, 7USC, Los Angelos, CA

    Background/Purpose: Adherence to urate-lowering therapy (ULT) reduces the incidence of debilitating gout flares. Providing a cue for a behavior, reinforcing the behavior with a reward,…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology